Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702989 | 0.93 | THRA (0.47) | MEN1NPC1ALDH1A1GAAMAPT | |
| SCHEMBL22683257 | 0.87 | MAOB (0.39) | MEN1NPC1ALDH1A1GAAMAPT | |
| SCHEMBL20031639 | 0.87 | ALB (0.44) | MAOBALDH2 | |
| SCHEMBL22683259 | 0.86 | BRD4 (0.48) | MEN1NPC1ALDH1A1GAAMAPT | |
| SCHEMBL22683260 | 0.81 | ITGB3 (0.43) | MAOB | |
| SCHEMBL25016883 | 0.81 | EGFR (0.42) | MIFMAOBEGFR | |
| SCHEMBL22683256 | 0.81 | BRD4 (0.53) | MAPTLTA4HMAOBEGFRALDH2 | |
| SCHEMBL20031910 | 0.80 | EGFR (0.44) | MEN1ALDH1A1GAAMAPTKMT2A | |
| SCHEMBL20031659 | 0.80 | MIF (0.44) | ALDH1A1GAAMIFMAOBEGFR | |
| SCHEMBL20031911 | 0.79 | MAOB (0.41) | THRATHRBMAOBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578040-B2 | [5]Helicene derivatives as molecular reporters for diagnostic applications and methods of synthesis therefor | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2023-02-14 | — | — | US | disclosed |
| EP-3518746-B1 | [5]HELICENE DERIVATIVES AS MOLECULAR REPORTERS FOR DIAGNOSTIC APPLICATIONS AND METHODS OF SYNTHESIS THEREFOR | NATIONAL SCIENCE AND TECH DEVELOPMENT AGENCY (TH) | 2020-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578040-B2 | [5]Helicene derivatives as molecular reporters for diagnostic applications and methods of synthesis therefor | OR51E2, HDHD5, WEE1 | MEN1 3486/4885NPC1 2225/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.